We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GEHC Launches MIM ComboTherapy for GYN Cancer Radiation Planning
Read MoreHide Full Article
Key Takeaways
GEHC launched MIM ComboTherapy for gynecologic cancer radiation therapy planning.
MIM ComboTherapy adds 3D dose summation using BED and EQD2 for precise dose evaluation.
GEHC shares gained 2.8% after unveiling the vendor-neutral radiation planning solution.
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced the launch of MIM ComboTherapy GYN HDR/EBRT, an advanced solution to improve radiation therapy planning for gynecologic cancers, including cervical and uterine cancers.
The technology supports managing complex combination therapies involving External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) brachytherapy. Since both therapies contribute to the patient’s cumulative radiation exposure, accurately calculating and visualizing total dose distribution is critical for effective treatment planning.
Management emphasized that women’s health has long lacked adequate innovation, particularly in gynecologic cancer care, where clinicians often relied on estimated radiation dose calculations. Solutions like MIM ComboTherapy GYN HDR/EBRT enhances clinicians’ ability to plan complex radiation treatments with greater confidence by offering clearer insights into total radiation doses. As cancer care moves toward personalized and data-driven strategies, innovations like this can enhance radiation therapy planning and improve quality of life.
Likely Trend of GEHC Stock Following the News
Shares of GEHC have gained 2.8% since the announcement on Wednesday. In the year-to-date period, shares of the company lost 22.6% compared with the industry’s 24.8% decline. However, the S&P 500 has risen 9.1% in the same timeframe.
The launch of MIM ComboTherapy GYN HDR/EBRT is expected to strengthen GEHC’s position in the radiation oncology market by enhancing its portfolio with advanced, data-driven treatment planning solutions. The innovation addresses a critical gap in gynecologic cancer care while increasing the adoption of precise and personalized radiation therapy tools. The solution reinforces GE HealthCare’s focus on women’s health and technological innovation, which could expand clinical partnerships and support long-term revenue growth in oncology imaging and software solutions.
GEHC currently has a market capitalization of $28.87 billion.
Image Source: Zacks Investment Research
More on the MIM ComboTherapy
MIM ComboTherapy introduces advanced 3D dose summation capabilities using Biological Effective Dose (BED) and Equivalent Dose in 2 Gy fractions (EQD2). These features better evaluate the biological impact of combined radiation treatments and identify high-dose accumulation areas, or “hotspots,” with greater precision.
The solution incorporates deformable image registration tools that help validate how prior radiation doses map onto the current patient anatomy. This is vital in gynecologic cancer cases, where anatomical changes caused by HDR applicators can complicate treatment planning and dose assessment.
With automation, standardized processes and vendor-neutral compatibility across treatment planning systems, MIM ComboTherapy is designed to integrate smoothly into existing clinical workflows and improve workflow efficiency for diverse clinical environments.
Industry Prospects Favoring the Market
Going by the data provided by Research and Markets, the radiation oncology treatment planning software market is valued at $2.74 billion in 2026 and is projected to reach $3.85 billion by 2030, expanding at a CAGR of 8.9% from 2026 to 2030.
Factors like the rising global cancer prevalence, growing demand for precision oncology solutions and adoption of advanced 3D modeling and AI-driven radiation therapy planning tools are boosting the market’s growth.
Other News
Recently, GE HealthCare exited the first quarter of 2026, wherein earnings missed estimates while revenues surpassed the same. Adjusted earnings per share fell short, reflecting pressure on profitability. However, top-line performance was driven by strong commercial execution in Pharmaceutical Diagnostics, including Flyrcado, Advanced Visualization Solutions and Imaging, as well as services across the United States, EMEA and Rest of World. Performance was impacted by a PDx supplier issue, tariff headwinds and elevated costs related to memory chips, oil and freight, which weighed on margins.
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 9.6% compared with the industry’s 13% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. It currently carries a Zacks Rank #2 (Buy).
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% rise. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%. It currently carries a Zacks Rank of 2.
Intuitive Surgical has a long-term estimated growth rate of 14.6% compared with the industry’s 13% rise. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
GEHC Launches MIM ComboTherapy for GYN Cancer Radiation Planning
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced the launch of MIM ComboTherapy GYN HDR/EBRT, an advanced solution to improve radiation therapy planning for gynecologic cancers, including cervical and uterine cancers.
The technology supports managing complex combination therapies involving External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) brachytherapy. Since both therapies contribute to the patient’s cumulative radiation exposure, accurately calculating and visualizing total dose distribution is critical for effective treatment planning.
Management emphasized that women’s health has long lacked adequate innovation, particularly in gynecologic cancer care, where clinicians often relied on estimated radiation dose calculations. Solutions like MIM ComboTherapy GYN HDR/EBRT enhances clinicians’ ability to plan complex radiation treatments with greater confidence by offering clearer insights into total radiation doses. As cancer care moves toward personalized and data-driven strategies, innovations like this can enhance radiation therapy planning and improve quality of life.
Likely Trend of GEHC Stock Following the News
Shares of GEHC have gained 2.8% since the announcement on Wednesday. In the year-to-date period, shares of the company lost 22.6% compared with the industry’s 24.8% decline. However, the S&P 500 has risen 9.1% in the same timeframe.
The launch of MIM ComboTherapy GYN HDR/EBRT is expected to strengthen GEHC’s position in the radiation oncology market by enhancing its portfolio with advanced, data-driven treatment planning solutions. The innovation addresses a critical gap in gynecologic cancer care while increasing the adoption of precise and personalized radiation therapy tools. The solution reinforces GE HealthCare’s focus on women’s health and technological innovation, which could expand clinical partnerships and support long-term revenue growth in oncology imaging and software solutions.
GEHC currently has a market capitalization of $28.87 billion.
Image Source: Zacks Investment Research
More on the MIM ComboTherapy
MIM ComboTherapy introduces advanced 3D dose summation capabilities using Biological Effective Dose (BED) and Equivalent Dose in 2 Gy fractions (EQD2). These features better evaluate the biological impact of combined radiation treatments and identify high-dose accumulation areas, or “hotspots,” with greater precision.
The solution incorporates deformable image registration tools that help validate how prior radiation doses map onto the current patient anatomy. This is vital in gynecologic cancer cases, where anatomical changes caused by HDR applicators can complicate treatment planning and dose assessment.
With automation, standardized processes and vendor-neutral compatibility across treatment planning systems, MIM ComboTherapy is designed to integrate smoothly into existing clinical workflows and improve workflow efficiency for diverse clinical environments.
Industry Prospects Favoring the Market
Going by the data provided by Research and Markets, the radiation oncology treatment planning software market is valued at $2.74 billion in 2026 and is projected to reach $3.85 billion by 2030, expanding at a CAGR of 8.9% from 2026 to 2030.
Factors like the rising global cancer prevalence, growing demand for precision oncology solutions and adoption of advanced 3D modeling and AI-driven radiation therapy planning tools are boosting the market’s growth.
Other News
Recently, GE HealthCare exited the first quarter of 2026, wherein earnings missed estimates while revenues surpassed the same. Adjusted earnings per share fell short, reflecting pressure on profitability. However, top-line performance was driven by strong commercial execution in Pharmaceutical Diagnostics, including Flyrcado, Advanced Visualization Solutions and Imaging, as well as services across the United States, EMEA and Rest of World. Performance was impacted by a PDx supplier issue, tariff headwinds and elevated costs related to memory chips, oil and freight, which weighed on margins.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
GEHC’s Zacks Rank & Key Picks
Currently, GEHC has a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 9.6% compared with the industry’s 13% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. It currently carries a Zacks Rank #2 (Buy).
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% rise. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%. It currently carries a Zacks Rank of 2.
Intuitive Surgical has a long-term estimated growth rate of 14.6% compared with the industry’s 13% rise. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.